Zanubrutinib plus R-CHOP for Double-Expressor Lymphoma
Study Overview
This study focuses on double-expressor lymphoma (DEL), which has a worse outlook than other types of diffuse large B-cell lymphoma (DLBCL). It evaluates the effectiveness and safety of combining zanubrutinib with the R-CHOP treatment (which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for patients with DEL at stage II or higher.
Study Details
From November 2020 to July 2022, 48 newly diagnosed patients participated. They received:
- Twice-daily oral zanubrutinib (160 mg) for 6 months
- Standard R-CHOP treatment for six to eight cycles
Results
The results showed:
- Objective Response Rate (ORR): 89.6%
- Complete Response Rate (CRR): 83.3%
- Median follow-up: 29.3 months
- Progression-Free Survival (PFS) at 2 years: 81.25%
- Overall Survival (OS) at 2 years: 93.75%
However, 47.9% of patients experienced grade ≥3 adverse events. Genetic testing revealed common mutations in TP53, MYD88, and PIM1. Additionally, certain genetic rearrangements and the number of extranodal involvements were linked to poorer outcomes.
Conclusions
Combining zanubrutinib with R-CHOP is a promising treatment for DEL patients, with manageable side effects.
Enhancing Clinical Practice
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research into an accessible resource for healthcare providers.
Streamlining Operations
In today’s healthcare landscape, efficiency is vital. Our mobile apps facilitate:
- Scheduling
- Monitoring treatments
- Telemedicine services
This makes patient care management easier and expands digital services.
Improving Patient Outcomes
By leveraging AI, clinics can enhance workflows, improve patient outcomes, and reduce reliance on paper processes. Learn more at aidevmd.com.
